Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Fragasso Financial Advisors Inc

Fragasso Financial Advisors Inc decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 66.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,941 shares of the medical research company's stock after selling 9,597 shares during the period. Fragasso Financial Advisors Inc's holdings in Charles River Laboratories International were worth $744,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Rothschild Investment LLC increased its holdings in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares during the period. Optiver Holding B.V. purchased a new position in Charles River Laboratories International during the 4th quarter valued at about $37,000. GeoWealth Management LLC increased its holdings in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International during the 4th quarter valued at about $48,000. Finally, Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the period. Institutional investors own 98.91% of the company's stock.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Up 3.5%

Shares of CRL stock traded up $4.83 during trading hours on Wednesday, hitting $143.32. The company had a trading volume of 849,402 shares, compared to its average volume of 993,520. The company's fifty day moving average is $128.17 and its 200 day moving average is $159.66. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The stock has a market capitalization of $7.04 billion, a PE ratio of 955.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the business earned $2.27 EPS. The firm's quarterly revenue was down 2.7% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRL has been the topic of a number of research analyst reports. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a report on Wednesday, May 14th. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a research report on Thursday, May 8th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Finally, Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).